Search clinical trials for: Octreotide Acetate in Microspheres

Total 158 results

Novartis

Completed

Octreotide Acetate in Microspheres in Patients With Diabetic Retinopathy

Diabetic Retinopathy

United States
Novartis Pharmaceuticals

Terminated

Extension Study of Long-term Safety and Tolerability of Octreotide Acetate in Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy or Low Risk Proliferative Diabetic Retinopathy

Diabetic Retinopathy
Novartis Pharmaceuticals

Terminated

Extension Study of the Long-term Safety and Tolerability of Octreotide Acetate in Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy or Low Risk Proliferative Diabetic Retinopathy

Diabetic Retinopathy
Novartis

Completed

Octreotide Acetate in Microspheres in Patients With Diabetic Retinopathy

Diabetic Retinopathy

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Terminated

Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors

Head and Neck Cancer | Metastatic Cancer | Pheochromocytoma | Islet Cell Tumor

United States
Qilu Pharmaceutical Co., Ltd.

Completed

Bioequivalence Study of Two Octreotide Microsphere Formulations in Healthy Volunteers

Healthy Volunteers

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

A Single-dose Study of Octreotide Injection in Healthy Adult Subjects

Acromegaly

China
Qilu Hospital of Shandong University

Not yet recruiting

A Real-world Study of Octreotide Microspheres in Chinese Patients With Neuroendocrine Tumors

Neuroendocrine Tumors

China
Azidus Brasil

Suspended

Pharmacodynamics Of Product Octreotide Acetate Lar 30 Mg Compared To Product Sandostatin LAR ®

Acromegaly

Brazil
Endo Pharmaceuticals

Completed

Open Label Study of Octreotide Implant in Patients With Acromegaly

Acromegaly
Novartis Pharmaceuticals

Terminated

Study Assessing the Efficacy and Safety of Octreotide Acetate in Patients With Acromegaly, With Micro or Macroadenomas

Acromegaly

Mexico
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Octreotide in Treating Patients With Cancer-Related Malignant Ascites

Unspecified Adult Solid Tumor, Protocol Specific | Metastatic Cancer

United States
University College, London
National Institute for Health Research, United Kingdom

Active, not recruiting

A Feasibility Study of Octreotide Infusion During Liver Transplant. (Octreotide)

Liver Transplantation | Renal Failure

United Kingdom
Lexicon Pharmaceuticals

Completed

Phase 1, Open-label, Drug-drug Interaction Study With Octreotide Acetate Injection and Telotristat Etiprate in Healthy Subjects

Drug Interactions

United States
Radiation Therapy Oncology Group
National Cancer Institute (NCI)

Completed

Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer

Colorectal Cancer | Anal Cancer | Drug/Agent Toxicity by Tissue/Organ | Radiation Enteritis

United States
Debiopharm International SA

Active, not recruiting

A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) (OXTEND-01)

Acromegaly | GEP-NET

United Kingdom, France, Spain, Italy, Poland, Denmark, Germany, Israel
Novartis Pharmaceuticals

Completed

Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly

Acromegaly

Germany
University Health Network, Toronto

Unknown

Fecal Calprotectin Levels in Mycophenolate Mofetil Induced Diarrhea and Treatment With Octreotide

Diarrhea | Immunosuppression

Canada
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis

Sarcoma | Cervical Cancer | Diarrhea | Colorectal Cancer | Ovarian Cancer | Fallopian Tube Cancer | Prostate Cancer | Unspecified Adult Solid Tumor, Protocol Specific | Vulvar Cancer | Endometrial Cancer | Vaginal Cancer
Northwestern University
National Cancer Institute (NCI)

Completed

Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery

Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Small Intestine Cancer | Ovarian Cancer | Peritoneal Cavity Cancer | Gastrointestinal Stromal Tumor | Extrahepatic Bile Duct Cancer | Nausea and Vomiting | Constipation, Impaction, and Bowel Obstruction

United States
Asan Medical Center
Novartis Korea Ltd.

Unknown

Hormonal Outcomes in Acromegalic Patients With Treated Surgery With or Without Long Acting Somatostatin Analogues (acromegaly)

Acromegaly

Korea, Republic of
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Octreotide in Treating Patients With Locally Advanced or Metastatic Liver Cancer

Liver Cancer

United States
Novartis Pharmaceuticals

Completed

Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients (HOSCAR)

Acromegaly

Italy, France, Portugal, Poland, Switzerland
Novartis Pharmaceuticals

Completed

Efficacy/Safety of Octreotide Acetate in Patients With Uncontrolled Acromegaly

Acromegaly

Italy
Eastern Cooperative Oncology Group
National Cancer Institute (NCI); Cancer and Leukemia Group B; SWOG Cancer Research...

Completed

Octreotide Compared With Loperamide Hydrochloride for Chemotherapy-Related Diarrhea in Patients With Colorectal Cancer

Diarrhea | Colorectal Cancer

United States
Ambrilia Biopharma, Inc.

Terminated

Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients

Acromegaly

United States, Belarus, Hungary, Serbia, Ukraine, Romania
Ambrilia Biopharma, Inc.

Completed

Efficacy and Safety of C2L-OCT-01 PR in Acromegalic Patients

Acromegaly

Belarus, Hungary, Romania, Serbia, Slovakia, Ukraine
Dauntless Pharmaceuticals

Completed

Study of Intranasal Octreotide (DP1038) in Healthy Adult Volunteers

Healthy Volunteer Study

United States
National Cancer Institute, Naples

Completed

Octreotide LAR in the Induction of Immunologic Response in NENs Patients (CSMS99)

Neuroendocrine Tumors

Italy
Luye Pharma Group Ltd.

Completed

Pharmacokinetics, Pharmacodynamics and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX®

Prostate Cancer

China
Luye Pharma Group Ltd.

Completed

Efficacy and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX®

Prostate Cancer

China
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Octreotide With or Without Prednisone in Treating Patients With Metastatic or Recurrent Thymoma

Thymoma and Thymic Carcinoma

United States, South Africa
Novartis Pharmaceuticals

Completed

Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis

Peritoneal Neoplasms | Intestinal Obstruction | Carcinomatosis

France
Novartis

Terminated

Octreotide in the Prevention of Diarrhea in Patients Receiving Irinotecan for Metastatic Colon Cancer

Diarrhea | Colorectal Cancer

United States
Emphycorp
Cellular Sciences, inc.

Completed

Inhaled Sodium Pyruvate for the Treatment of Cystic Fibrosis.

Cystic Fibrosis

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Fludarabine Plus Octreotide in Treating Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma

Lymphoma

United States, Canada
Sue O'Dorisio
National Cancer Institute (NCI)

Completed

Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT

Neuroendocrine Tumor | Neuroblastoma | Somatostatinoma | Adult Medulloblastoma | Childhood Medulloblastoma

United States
Luye Pharma Group Ltd.

Completed

Efficacy and Safety of LY01005 in Patients With Breast Cancer Compared to ZOLADEX®

Breast Cancer

China
Jinling Hospital, China

Completed

Autologous Fibrin Glues for Fistulas Closure

Intra-abdominal Infection | Enterocutaneous Fistulas

China
University of Pittsburgh
National Cancer Institute (NCI)

Completed

Octreotide and Doxorubicin in Treating Patients With Advanced Cancer

Unspecified Adult Solid Tumor, Protocol Specific

United States
Luye Pharma Group Ltd.

Not yet recruiting

Pharmacokinetics Pharmacodynamics and Safety of LY01022 in Patients With Prostate Cancer Compared With Zoladex® 10.8mg

Prostate Cancer

China
MedSIR
MacroGenics; Seagen Inc.

Withdrawn

Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast Cancer (MARGARET)

Advanced Breast Cancer | Metastatic Breast Cancer | HER2-positive Breast Cancer
First Affiliated Hospital, Sun Yat-Sen University

Unknown

Protective Effect of Lipo-PGE1 on Myocardial Injury Following Percutaneous Coronary Intervention (PGEACS)

Percutaneous Coronary Intervention | Prostaglandin E1

China
Nicholas Fidelman, MD
Merck Sharp & Dohme LLC; BTG International Inc.

Active, not recruiting

Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases

Neuroendocrine Neoplasm | Metastatic Malignant Neoplasm in the Liver

United States
University Hospital, Basel, Switzerland

Completed

Oral Glucosestimulation After Gastric Bypass Surgery

Obesity

Switzerland
NCIC Clinical Trials Group

Completed

Tamoxifen With or Without Octreotide in Treating Postmenopausal Women With Stage I, Stage II, or Stage III Breast Cancer

Breast Cancer

Canada, United States
Mennatallah Mohamed Elnemr

Unknown

Best Cutoff Value of Lactate Concentration in Vaginal Fluid to Predict Time of Spontaneous Onset of Labor in PPROM

Aim is to Investigate Association Between Lactate Concentration in Vaginal Fluid and Time of Spontaneous Onset of Labor in PPROM

Egypt
Aga Khan University
Zeenat Qureshi Stroke Institute

Recruiting

Best Solution Identification to Prevent Hyperchloremia Combinations of Sodium Chloride and Sodium Acetate IV Fluids Along With Standard of Care Treatment in Acute Stroke Patients (sodium acetate)

Stroke, Acute

Pakistan
University of Southern California
National Cancer Institute (NCI); Sanofi

Terminated

Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel

Diarrhea | Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer

United States
Columbia University
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Albert...

Not yet recruiting

Dexamethasone/Pancreatic Clamp P&F

Insulin Resistance | Prediabetic State | Overweight and Obesity | Non-Alcoholic Fatty Liver Disease

United States

Search clinical trials for: Octreotide Acetate in Microspheres

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jordan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations